Related Experiment Videos
Bone marrow purging for multiple myeloma by avidin-biotin immunoadsorption
R M Lemoli1, M Gobbi, P L Tazzari
1Istituto di Ematologia Seragnoli, Università di Bologna, Italy.
Transplantation
|February 1, 1989
Summary
Avidin-biotin immunoadsorption effectively removes over 98% of neoplastic plasma cells from bone marrow. This technique shows promise for ex-vivo bone marrow manipulation in multiple myeloma patients, preserving essential progenitor cells.
Area of Science:
- Immunology
- Hematology
- Biotechnology
Background:
- Multiple myeloma involves neoplastic plasma cells infiltrating bone marrow.
- Ex-vivo bone marrow purging is crucial for autologous transplantation.
- Avidin-biotin technology offers high specificity for cell targeting.
Purpose of the Study:
- To evaluate the efficacy of avidin-biotin immunoadsorption for removing neoplastic plasma cells from multiple myeloma bone marrow.
- To assess the impact of this technique on hematopoietic progenitor cell recovery.
- To determine the optimal monoclonal antibodies (MoAb) for plasma cell depletion.
Main Methods:
- Bone marrow buffy coat cells from 25 multiple myeloma patients were used.
- Cells were incubated with specific anti-plasma cell monoclonal antibodies (MoAb) and biotinylated antibodies.
- Cells were passed through an avidin-conjugated Sepharose column for immunoadsorption.
Main Results:
- Over 98% plasma cell removal was achieved using single MoAb (8A or 8F6).
- Combined MoAb (8A + 8F6 or 62B1) resulted in 99.5% +/- 0.4% plasma cell purging.
- Hematopoietic progenitor recovery varied: CFU-GM (39-50%), BFU-e (15-39%), CFU-GEMM (16-64%) depending on MoAb used.
Conclusions:
- Avidin-biotin immunoadsorption is a highly effective method for ex-vivo purging of neoplastic plasma cells.
- The technique demonstrates potential for clinical application in multiple myeloma treatment.
- Further optimization of MoAb cocktails may improve progenitor cell recovery while maintaining high plasma cell depletion.